Deal with Singapore’s MuseCell Innovations could bring $300 million in business and 200 jobs to Celularity’s cell platform.
Deals in cell therapy tend to get announced in two flavors: the kind built around a single drug, and the kind built around infrastructure. This unglamorous plumbing decides whether any of these therapies can actually be made at scale. The agreement between Celularity and MuseCell Innovations is squarely the second kind, and the numbers attached to it suggest it’s not a small one.
Celularity, the Nasdaq-listed regenerative medicine company built around placenta-derived cell therapies, will begin manufacturing “Dezawa MuseCells” (DMCs, for short) at its Florham Park, New Jersey facility, under license from MuseCell Innovations (MCI), the Singapore-based owner of the platform [1].
Muse cells were discovered by Professor Mari Dezawa, who described them as a naturally occurring, stress-enduring cell population – cells that survive conditions that would kill most others, a trait that’s made them a subject of more than 170 peer-reviewed papers and multiple human clinical studies over the years. The initial phase of the deal covers manufacturing DMCs from perinatal sources, along with two related products, Dezawa MuseExosomes and Dezawa MuseSecretome, each with its own dedicated production process and quality specifications.
It’s a narrower starting point than it might sound. Under the MCI platform, a batch of cells only counts as an authenticated DMC product if it’s made under the licensed “Dezawa Method” and meets MCI’s own specifications, not simply because it came from a qualifying tissue source.
“The central scientific and quality principle is that Dezawa MuseCell identity is defined by manufacture under the licensed Dezawa Method and conformance to MCI’s product specifications – not by the anatomical source alone,” said Dominik Duscher, MCI’s chief executive and president.
The initial manufacturing project is really a proof of concept for something larger. Based on current market conditions and MCI’s own projections, the companies believe an expanded partnership covering additional products and programs could generate more than $300 million in aggregate purchases from Celularity over the next five years, and more than 200 high-tech jobs at the Florham Park site, in specialties ranging from biomanufacturing to quality control and engineering.
“Cellular medicine remains at the center of Celularity’s strategy, including our continued advancement of our proprietary placental-derived technologies,” said Robert J Hariri, Celularity’s founder, chairman and chief executive. “Our collaboration with MCI demonstrates how the manufacturing infrastructure and cellular expertise we have built can also support innovative third-party technologies.”
New Jersey Governor Mikie Sherrill weighed in, too, framing the deal in economic-development terms.
“By bringing $300 million in business and more than 200 new jobs to New Jersey, Celularity and MuseCell Innovations are making it clear that our state is open for business… Advanced biomanufacturing continues to grow as a strong pillar of our economy,” she said.
None of this works without the physical plant to back it up. Celularity’s Florham Park facility spans 147,215 square feet, with nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites, the kind of cleanroom classification system that governs how sterile an environment needs to be for a given stage of cell production. It’s the same site where Celularity already manufactures cenplacel-L, its own placental-derived cell therapy, meaning the MCI collaboration is layering onto existing capacity rather than starting from scratch.
Celularity describes itself, plainly, as a longevity-focused regenerative medicine company, and this deal is a reminder of what that actually looks like in practice: not a single breakthrough therapy, but the unsexy work of building manufacturing capacity that lets an entire category of cell-based treatments reach patients reliably and at volume.
Muse cells are still an investigational tool rather than an approved therapy. Still, the ability to scale their production in the US, under a defined quality standard, is the kind of groundwork that determines whether promising aging-related cell science ever makes it out of the lab.
READ MORE: Stem cell pioneer launches in the United States
